Drugs / KUC 7483 CL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02259764 | Aug → Sep 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259933 | Feb → May 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259751 | Feb 2004 → Feb 2005 | spinal cord injury | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02259920 Comparator | Dec 2003 → May 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KUC-7483 CL | “Open Label, Randomized, Single-dose, Five-way Crossover Study to Investigate the Regional Drug Absorption of 80 mg KUC-7483 CL Administered Via an Enterion™ Capsule Compared to...” NCT02259920 ↗ |
| Route | Oral | “Single Oral Dose” NCT02259751 ↗ |